May 22nd 2025
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.
Watch the series now!
Dr Brian Koffman Highlights the Benefits and Risks of CAR T Therapy
FDA Gives Speedy Approval to Brentuximab for Peripheral T-Cell Lymphoma
Dr Marcus Neubauer Discusses the Evolution of Care Teams in Oncology
Cancer Surpasses CVD as Leading Cause of Death in High-Income Counties
Nobel Prize Winner Dr James Allison on the Impact His Work Has Made
Hispanics Living With HIV at Increased Risk of HPV-Related Cancers
Learnings From Priority Health's Oncology Payment Reform Model
Dr Lalan Wilfong Provides an Overview of Key Learnings From the OCM